AstraZeneca Acquires EsoBiotec For Up To $1B To Accelerate In Vivo Cell Therapy Innovation

AstraZeneca has completed its acquisition of EsoBiotec, a Belgium-based biotech firm developing in vivo cell therapies through its proprietary Engineered NanoBody Lentiviral (ENaBL) platform. This cutting-edge technology enables genetic reprogramming of immune cells, such as T cells, to target cancer or autoimmune disease, delivered in minutes via a simple IV injection, bypassing the complex and time-consuming manufacturing process typical of traditional cell therapies.

The ENaBL platform uses targeted lentiviral vectors to deliver genetic instructions directly to immune cells in the body. This process eliminates the need for immune cell depletion or weeks-long ex vivo cell engineering, potentially widening patient access to transformative cell therapies for cancer and immune-mediated diseases. AstraZeneca sees the platform as a major leap forward in the speed, accessibility, and scalability of personalized medicine.

Under the terms of the deal, AstraZeneca acquired EsoBiotec for up to $1 billion, including $425 million upfront and $575 million in milestone-based payments. As of now, AstraZeneca completely owns EsoBiotec. AstraZeneca expects the acquisition to have no impact on its 2025 financial outlook.